X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ophthalmology (44) 44
2.0 mg ranibizumab (43) 43
index medicus (43) 43
humans (35) 35
macular degeneration (35) 35
intravitreal injections (28) 28
efficacy (24) 24
vascular endothelial growth factor a - antagonists & inhibitors (23) 23
safety (22) 22
ranibizumab (21) 21
aged (20) 20
angiogenesis inhibitors - therapeutic use (19) 19
bevacizumab (19) 19
female (19) 19
male (19) 19
endothelial growth-factor (18) 18
wet macular degeneration - drug therapy (18) 18
degeneration (17) 17
vascular endothelial growth factor (15) 15
angiogenesis inhibitors - administration & dosage (14) 14
middle aged (14) 14
optical coherence tomography (14) 14
tomography, optical coherence (14) 14
treatment outcome (14) 14
aged, 80 and over (13) 13
therapy (13) 13
aflibercept (12) 12
care and treatment (12) 12
choroidal neovascularization (12) 12
intravitreal ranibizumab (12) 12
visual acuity (12) 12
age (11) 11
outcomes (11) 11
wet macular degeneration - diagnosis (11) 11
2.0 mg (10) 10
age-related macular degeneration (10) 10
genetic structures (10) 10
macular degeneration - drug therapy (10) 10
retrospective studies (10) 10
visual acuity - physiology (10) 10
wet macular degeneration - physiopathology (10) 10
ranibizumab - administration & dosage (9) 9
analysis (8) 8
follow-up studies (8) 8
physiological aspects (8) 8
receptors, vascular endothelial growth factor - therapeutic use (8) 8
recombinant fusion proteins - therapeutic use (8) 8
retina (8) 8
antibodies, monoclonal, humanized - therapeutic use (7) 7
photodynamic therapy (7) 7
pigment epithelial detachment (7) 7
verteporfin (7) 7
clinical trials (6) 6
injection (6) 6
intravitreal aflibercept (6) 6
intravitreal aflibercept injection (6) 6
patients (6) 6
prospective studies (6) 6
ranibizumab - therapeutic use (6) 6
vegf trap (6) 6
visual-acuity (6) 6
angiogenesis inhibitors - adverse effects (5) 5
anti-vascular endothelial growth factor (5) 5
anti-vegf (5) 5
choroidal neovascularization - drug therapy (5) 5
endothelial growth factors (5) 5
eye (5) 5
eye diseases (5) 5
macula (5) 5
macular degeneration - diagnosis (5) 5
medicine, research & experimental (5) 5
polypoidal choroidal vasculopathy (5) 5
review (5) 5
sense organs (5) 5
time factors (5) 5
acuity (4) 4
angiogenesis (4) 4
anti-vegf therapy (4) 4
bevacizumab - administration & dosage (4) 4
diabetic macular edema (4) 4
dosing regimen (4) 4
double-blind method (4) 4
drug administration schedule (4) 4
drug resistance (4) 4
fluid (4) 4
pharmacology & pharmacy (4) 4
regimen (4) 4
research (4) 4
retinal angiomatous proliferation (4) 4
retinal detachment - drug therapy (4) 4
trial (4) 4
visual acuity - drug effects (4) 4
abridged index medicus (3) 3
age related macular degeneration (3) 3
amd (3) 3
bevacizumab - adverse effects (3) 3
clinical protocols (3) 3
diabetic retinopathy (3) 3
diabetic retinopathy - drug therapy (3) 3
diagnosis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Ophthalmology, ISSN 0161-6420, 06/2019, Volume 126, Issue 6, pp. 849 - 855
Purpose: A simulated switching study assessed the effects of continuing the same anti–vascular endothelial growth factor (VEGF) treatment among patients who... 
OPHTHALMOLOGY | AFLIBERCEPT | 2.0 MG RANIBIZUMAB | EFFICACY | SAFETY
Journal Article
British Journal of Ophthalmology, ISSN 0007-1161, 07/2014, Volume 98, Issue 7, pp. 951 - 955
Journal Article
Eye (Basingstoke), ISSN 0950-222X, 12/2017, Volume 31, Issue 12, pp. 1697 - 1706
Purpose To examine 12-month real-world visual acuity outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes, including... 
2.0 MG RANIBIZUMAB | INTRAVITREAL RANIBIZUMAB | OPTICAL COHERENCE TOMOGRAPHY | TREATMENT PATTERNS | BEVACIZUMAB | PIGMENT EPITHELIAL DETACHMENT | OPHTHALMOLOGY | MACULAR DEGENERATION | VEGF TRAP | GROWTH-FACTOR | CHOROIDAL NEOVASCULARIZATION | Macular degeneration | Eye | Medical records | Degeneration | Mathematical models | Age | Acuity | Index Medicus | Clinical Study
Journal Article
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 08/2019, Volume 19, Issue 8, pp. 735 - 751
Journal Article
Graefe's Archive for Clinical and Experimental Ophthalmology, ISSN 0721-832X, 05/2018, Volume 256, Issue 5, pp. 963 - 973
Journal Article
EYE, ISSN 0950-222X, 11/2015, Volume 29, Issue 11, pp. 1428 - 1436
Purpose To determine safety and efficacy of intravitreal high-dose ranibizumab in the treatment of active neovascular polypoidal choroidal vasculopathy (PCV).... 
RESIDUAL EXUDATION | EPITHELIUM-DERIVED FACTOR | OBSTRUCTIVE SLEEP-APNEA | 2.0 MG RANIBIZUMAB | INTRAVITREAL RANIBIZUMAB | PHOTODYNAMIC THERAPY | EFFICACY | OPHTHALMOLOGY | MACULAR DEGENERATION | BLOOD-FLOW | ENDOTHELIAL GROWTH-FACTOR
Journal Article
Journal Article
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 2, pp. 145 - 150
Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular... 
poly(lactic-co-glycolic acid) (PLGA) | controlled release | anti-vascular endothelial growth factor (VEGF) therapy | age-related macular degeneration (AMD) | ranibizumab | biosimilar | Anti-vascular endothelial growth factor (VEGF) therapy | Poly(lactic-co-glycolic acid) (PLGA) | Age-related macular degeneration (AMD) | Biosimilar | Controlled release | Ranibizumab | CO-ENCAPSULATION | 2.0 MG RANIBIZUMAB | MICROSPHERES | DRUG-RELEASE | DEGENERATION | DELIVERY | IN-VITRO | VERTEPORFIN | PLGA MICROPARTICLES | PHARMACOLOGY & PHARMACY | DIABETIC MACULAR EDEMA | Drug Carriers - metabolism | Human Umbilical Vein Endothelial Cells - drug effects | Biosimilar Pharmaceuticals - administration & dosage | Human Umbilical Vein Endothelial Cells - metabolism | Humans | Lactic Acid - metabolism | Drug Carriers - administration & dosage | Vascular Endothelial Growth Factor A - metabolism | Delayed-Action Preparations - administration & dosage | Delayed-Action Preparations - metabolism | Microspheres | Ranibizumab - administration & dosage | Polyglycolic Acid - metabolism | Biosimilar Pharmaceuticals - metabolism | Ranibizumab - metabolism | Vascular Endothelial Growth Factor A - administration & dosage | Drug Delivery Systems - methods | Lactic Acid - administration & dosage | Polyglycolic Acid - administration & dosage | Biodegradation | Cell proliferation | Biodegradable materials | Biodegradability | Radioactive half-life | Microparticles | Molecular weight | Endothelial cells | Polylactide-co-glycolide | Macular degeneration | Eye | Angiogenesis | Acids | Proteolysis | Sustainability | Glycolic acid | Degeneration | Vascular endothelial growth factor | Age | Index Medicus
Journal Article
Journal Article
OPHTHALMOLOGY, ISSN 0161-6420, 10/2016, Volume 123, Issue 10, pp. S78 - S88
The association of retinal hypoxia with retinal neovascularization has been recognized for decades, causing Michaelson to postulate in 1948 that a factor... 
OCCLUSION 12-MONTH OUTCOMES | 2.0 MG RANIBIZUMAB | PROLIFERATIVE DIABETIC-RETINOPATHY | MACULAR EDEMA SECONDARY | INTRAVITREAL AFLIBERCEPT INJECTION | LONG-TERM OUTCOMES | OPHTHALMOLOGY | VEIN OCCLUSION | VEGF TRAP-EYE | CHOROIDAL NEOVASCULARIZATION | BEVACIZUMAB AVASTIN THERAPY
Journal Article
Ophthalmology, ISSN 0161-6420, 06/2018, Volume 125, Issue 6, pp. 878 - 886
To evaluate macular atrophy (MA) presence in the 24-month HARBOR study ( ) for neovascular age-related macular degeneration (AMD). Post hoc analysis of a phase... 
EYE DISEASE | 2.0 MG RANIBIZUMAB | RETICULAR PSEUDODRUSEN | TREATMENTS TRIALS | OPHTHALMOLOGY | FOLLOW-UP | RETINAL ANGIOMATOUS PROLIFERATION | OUTCOMES | CHOROIDAL NEOVASCULARIZATION | GEOGRAPHIC-ATROPHY | HORIZON | Macular degeneration | Physiological aspects | Analysis | Index Medicus
Journal Article
国际眼科杂志:英文版, ISSN 2222-3959, 2018, Volume 11, Issue 2, pp. 267 - 273
Journal Article